Breaking Finance News

RBC Capital Markets issued a report on Karyopharm Therapeutics (NDAQ:KPTI), raising its target price to $14.00 today

Only yesterday Karyopharm Therapeutics (NDAQ:KPTI) traded 3.97% higher at $10.95. Karyopharm Therapeutics’s 50-day average is $9.22 and its two hundred day average is $9.87. With the last stock price up 11.34% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the date range. Trading volume was down over the average, with 106,214 shares of KPTI changing hands under the typical 172,938

In a report announced on 9/15/2017 RBC Capital Markets bumped up the target of Karyopharm Therapeutics (NDAQ:KPTI) to $14.00 reporting a possible upside of 0.28%.

See Chart Below

Karyopharm Therapeutics (NDAQ:KPTI)

Karyopharm Therapeutics has with a one year low of $6.27 and a one year high of $14.63 and has a total market value of $0.

A total of 9 brokerages have issued a ratings update on the company. 3 brokers rating the stock a strong buy, 3 analysts rating the company a buy, one analyst rating the company a hold, 1 brokerage rating the stock a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $16.56.

More About Karyopharm Therapeutics (NDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.